STL Index for: Isotretinoin
Casmo Prevention and Management of Four Common Cutaneous Toxicities Associated with Targeted Cancer Therapies: Papulopustular Eruption, Xerosis, Paronychia, and...
Advances in cancer treatment have contributed to a reduction in mortality but survivors and healthcare providers should be aware of the potential adverse effects of these advanced treatments.
The proper and suitable application of antibiotics is crucial in maintaining their effectiveness amidst growing antibiotic resistance. Nevertheless, it is essential for prescribing practitioners to have a heightened understanding of resistance causes and strategies to counteract them.
This review details the rosacea phenotype approach to diagnosis and classification, and summarizes current evidence-based treatment recommendations for individual features.
Evolving understanding of the role of hormones in acne, along with a growing body of data from clinical trials, calls for a reappraisal of the role of hormonal therapy for acne.
The focus of this review is to delve deeper into the use of Biacna® Gel, a fixed-dose clindamycin/tretinoin combination product, for the treatment of acne.
Truncal acne refers to AV affecting the chest and/or back, a common presentation in acne patients. This article offers guidance in clinical differentiation of truncal acne from other acneiform diseases and provides management recommendations.
Physicians will be particularly reassured if the suggested guidelines are supported by scientific evidence. This new Canadian clinical guideline for the treatment of acne was developed taking into account new data published up to March 2015, as well as expert opinion and clinical experience.
Hidradenitis suppurativa (HS) is a chronic disease of the follicular unit that often leads to marked impairment of quality of life. This article reviews various treatment modalities for HS including laser, surgery, retinoids, immunosuppression, biologics, and antibiotics.
Acne vulgaris is a multifactorial disease characterized by different types of lesions at various stages of development. Treatment options, such as light based therapy and systemic therapy, as well as CIS-Isotretinoin (Epuris™) that increases absorption are discussed as well as patient adherence.
Current practice guidelines recommend administration of oral isotretinoin with high-fat meals, which may pose issues with patient compliance. This article discusses Isotretinoin-Lidose (Epuris™), pharmacokinetics, bioavailability, and increased drug absorption rate, and how it may improve patient compliance.
Skin Treatments Introduced in 2012 including CIP-Isotretinoin capsule Epuris™(in Canada) Absorica™(in US), Lidocaine 7% + tetracaine 7% cream Pliaglis®, Collagenase clostridium histolyticum Xiaflex®, C1 esterase inhibitor (human) Cinryze®, Ipilimumab Yervoy™, and Vemurafenib tablets Zelboraf™.
Skin Treatments Introduced in 2012. Adapalene 0.1% + benzoyl peroxide 2.5% gel (Epiduo®), Adapalene 0.3% gel (Differin®), Tazarotene 0.1% foam (Fabior™), CIP-Isotretinoin capsule Epuris™ (in Canada) Absorica™ (in US), Ingenol mebutate gel (0.015%, 0.05%) Picato®and more are covered.
An overview and update of skin treatments introduced in 2012: Quick overview of drug name, indications and regulatory status. Adapalene 0.1% + benzoyl peroxide 2.5% gel (Epiduo®), Adapalene 0.3% gel (Differin®), Tazarotene 0.1% foam (Fabior™), CIP-Isotretinoin capsule Epuris™ (in Canada) Absorica™ (in US) and more drugs are covered.
February 2013: Update on drugs, approval dates, and comments. Varicella zoster immune globulin (human) injection (Varizig®), Lidocaine 7% + tetracaine 7% cream (Pliaglis®), Isotretinoin capsule (Epuris™) are covered. Devices such as Laser hair therapy iGrow® Hair Growth Platform and LED device for acne Celluma™ are also covered.
Rosacea is a common chronic skin disorder that has significant impact on the quality of life of affected individuals. Research interest has led to the development of other emerging therapies including topical ivermectin, brimonidine and oxymetazoline that hold promise for patients suffering from this condition.
Update on drugs, approval dates, and comments. CIP-Isotretinoin (Absorica™), Tazarotene 0.1% foam (Fabior™), Butoconazole nitrate 2% vaginal cream, Multisource radiofrequency aesthetic device (Glow by EndyMed™), Low-level laser for circumferential upper arm reduction (Zerona®) are covered.
Solid organ transplant recipients have an increased incidence of skin cancer, resulting in significant morbidity and mortality post-transplantation. This article studies systemic retinoids, and other chemopreventative agents for high risk patients.
Acne treatment success involves a comprehensive approach that addresses diagnostic confounders, appropriate therapeutic options and patient adherence. Ongoing education and counselling will assist in meeting patient expectations and establishing a favourable rapport that promotes adherence.
Isotretinoin, better known by its trade name Accutane®, and its side-effects are discussed with an emphasis on the most common side-effects that patients reports, such as dryness of the skin, and irritation of the eyes.
Isotretinoin (Accutane) is a powerful drug, but one that has powerful side-effects. This article focuses on the side-effects that require monitoring as the symptoms may not be obvious to the patients.
Isotretinion is a powerful drug, and sometimes the only treatment option for severe acne. The most common side-effects such as dry skin, dry eyes, and hair problems, and headaches, and other side-effects are discussed.
Isotretinion will require monitoring by a doctor. While relatively rare, side-effects can be serious, and affect blood, bone, liver, neurologic, and muscle, and require periodic testing to ensure safety and healthy. It is also teratogenic, so pregnancy will also be a part in patient education.
Update on Loratadine Dry Syrup 1% Claritin® Schering-Plough, Valacyclovir Hydrochloride TEVA Pharmaceutical Industries, and news about Anti-dandruff, anti-acne and anti-melanoma agents.
Cutaneous Reactions to Anticancer Agents Targeting the Epidermal Growth Factor Receptor: A Dermatology-Oncology Perspective
The epidermal growth factor receptor (EGFR) is often overexpressed or dysregulated in solid tumors. Targeting the EGFR-mediated signaling pathway has become routine practice in the treatment of lung, pancreatic, head and neck, and colon carcinomas.
This article describes how pharmacists can play an important role in providing for patients with their skin concerns and counselling patients on effective management and behavioral strategies as well as prescribing. Reactive and proactive communication approaches are described.
Accutane (Isotretinoin) was approved for the treatment of acne. While in recent years it has been shrouded by some controversy, it remains an essential tool in the treatment of severe or persistent acne. Few drugs provide an actual cure for acne and Isotretinoin is such a medication.
Accutane® (Isotretinoin) Side Effects, Safety and Risks are discussed. A comprehensive review of the drug, side-effects, and other considerations.
Proper patient counselling of the risks versus benefits of Accutane® (Isotretinoin) treatment is very important to ensure compliance with therapy.
12Page 1 of 2